[PDF][PDF] Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell …
M Ogura, T Ishida, K Hatake, M Taniwaki… - Journal of Clinical …, 2014 - Citeseer
M Ogura, T Ishida, K Hatake, M Taniwaki, K Ando, K Tobinai, K Fujimoto, K Yamamoto…
Journal of Clinical Oncology, 2014•CiteseerPurpose CC chemokine receptor 4 (CCR4) is expressed by peripheral T-cell lymphomas
(PTCLs) and is associated with poor outcomes. Mogamulizumab (KW-0761) is a
defucosylated humanized anti-CCR4 antibody engineered to exert potent antibody-
dependent cellular cytotoxicity. This multicenter phase II study evaluated the efficacy and
safety of mogamulizumab in patients with relapsed PTCL and cutaneous T-cell lymphoma
(CTCL).
(PTCLs) and is associated with poor outcomes. Mogamulizumab (KW-0761) is a
defucosylated humanized anti-CCR4 antibody engineered to exert potent antibody-
dependent cellular cytotoxicity. This multicenter phase II study evaluated the efficacy and
safety of mogamulizumab in patients with relapsed PTCL and cutaneous T-cell lymphoma
(CTCL).
Purpose
CC chemokine receptor 4 (CCR4) is expressed by peripheral T-cell lymphomas (PTCLs) and is associated with poor outcomes. Mogamulizumab (KW-0761) is a defucosylated humanized anti-CCR4 antibody engineered to exert potent antibody-dependent cellular cytotoxicity. This multicenter phase II study evaluated the efficacy and safety of mogamulizumab in patients with relapsed PTCL and cutaneous T-cell lymphoma (CTCL).
Citeseer